DALS Insider Trading Activity and SEC Form 4 Filings
DALS insider trading summary
No open-market insider purchases or sales of DA32 Life Science Tech Acquisition Corp. (DALS) have been reported on SEC Form 4 in the past 12 months.
Latest DALS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 30, 2021 | Keith Crandell | Director | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | ARCH Venture Fund XI, L.P. | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | ARCH Venture Partners XI, L.P. | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | ARCH Venture Partners XI, LLC | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | Robert Nelsen | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | Kristina Burow | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | Steven Gillis | 10% Owner | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | Deerfield Management Company, L.P. (series C) | Director | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | Deerfield Partners, L.P. | Director | Buy | $16.0M (1,600,000 @ $10.00) |
| Jul 30, 2021 | James E Flynn | Director | Buy | $16.0M (1,600,000 @ $10.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.